Senior Research Associate, ADME (Contractor)
- Employer
- Sutro Biopharma, Inc
- Location
- South San Francisco, CA
- Salary
- $110,000 - $140,000
- Start date
- Jul 20, 2024
View more categoriesView less categories
- Discipline
- Regulatory, Research/Documentation, Science/R&D, Research
- Required Education
- Bachelors Degree
- Position Type
- Full time
- Hotbed
- Biotech Bay, Best Places to Work
Job Details
- Develop stage appropriate LC-MS/MS methods to quantify small molecule payloads and linker-payloads in biological matrices.
- Conduct in vitro ADME experiments including but not limited to enzymatic payload release, metabolic stability studies in biological matrices (hepatocytes, microsomes, blood, plasma etc.), plasma/blood partitioning, and plasma protein binding according to defined protocols under general guidance.
- Identify small molecule metabolites and ADC catabolites using high-resolution mass spectrometer in support of non-clinical or clinical studies.
- Assess drug-to-antibody ratio (DAR) stability both in vitro and in vivo.
- Analyze, interpret, and summarize data to understand metabolic/catabolic pathways, and present findings to project teams.
- BS or MS in the field of DMPK, analytical chemistry or related with a minimum of 5+ (for BS) or 1+ (for MS) years of relevant industry experience.
- Demonstrated ability to conduct in vitro ADME assays following the established protocols.
- Strong background on LC-MS operation including both Triple Quad and High-Resolution Mass Specs (hands-on experience with SCIEX 7500 QTrap and 7600 QToF is preferred)
- Working experience with ADC is a plus.
- Excellent communication skills and a team player mindset.
Company
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
Stock Symbol: STRO
Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more" - view it here
- Website
- http://www.sutrobio.com/
- Phone
- 650.881.6500
- Location
-
111 Oyster Point Blvd
South San Francisco
California
94080
US
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert